Genomics and Precision Medicine
Nov
2026
Description
This session presents genomic and molecular discoveries in liver disease, spanning cirrhosis risk loci, single-cell/spatial transcriptomics in hepatoblastoma, and population-scale genetic variant studies in MASLD and HCC.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 2DEF
meta-analysis of alcohol-associated liver cirrhosis identified new risk loci
Callie J Zaborenko, PhD | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 2DEF
Loss of Y chromosome is a novel somatic aneuploidy and potential biomarker in hepatocellular carcinoma
Gopanandan Parthasarathy, MBBS | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - Bluebird Ballroom 2DEF
Multi-ancestry whole-genome study identifies population-specific effects of PNPLA3, TM6SF2, MBOAT7, HSD17B13, and MARC1 on cirrhosis, MASLD, and hepatocellular carcinoma in 414,830 All of Us participants
Hyunseok Kim, MD, MPH, PhD | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - Bluebird Ballroom 2DEF
Epigenetic-Metabolic Phospholipid Reprogramming by BAP1 Loss Confers Cholangiocarcinoma Resistance to Ferroptosis
Yu Zhao, PhD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - Bluebird Ballroom 2DEF
Single-Cell, Single-Nuclei, and Spatial Transcriptomics Reveals Signature-Specific Microenvironments in Hepatoblastoma
Abhishek Murti, MS | Abstract Presenter
6:15 PM
- 6:30 PM
Convention Center - Bluebird Ballroom 2DEF
SPATIALLY RESOLVED LINEAGE PROGRAMS DEFINE PROGNOSIS, THERAPEUTIC VULNERABILITIES, AND STROMAL CROSSTALK IN INTRAHEPATIC CHOLANGIOCARCINOMA
KENTA MAKINO, MD, PhD | Abstract Presenter
